FORE Biotherapeutics today announced the appointment of Michael Byrnes as chief financial officer of the company. Mr. Byrnes brings over 20 years’ experience in the biotechnology industry, both in private and public companies, spanning all phases of development from pre-clinical to pre-commercial stages and across multiple indications. As CFO, he has led multiple companies through equity and debt transactions and been involved in M&A totaling close to $4B.

Prior to joining Fore, Mr. Byrnes was chief financial officer for eFFECTOR Therapeutics where he took the company public in 2021. Previous to that, Mr. Byrnes was senior vice president of finance at Principia Biopharma, Inc. (PRNB), which was acquired by Sanofi in September 2020. Prior to that, Mr. Byrnes served as chief financial officer of Alkahest, Inc. and chief financial officer of Ocera Therapeutics, Inc. (OCRX) until its acquisition by Mallinckrodt Pharmaceuticals. Earlier in his career, Mr. Byrnes held finance positions of increasing responsibility with Maxygen, Inc. (MAXY), NeurogesX, Inc. (NGSX), Lipid Sciences, Inc. (LIPD) and ADAC Laboratories, Inc. (ADAC). Mr. Byrnes received his B.S.C. in finance from Santa Clara University and an M.B.A. from California State University, Hayward.

Bill Hinshaw, CEO of Fore commented: “I am excited to have Mike join as our CFO. He brings highly relevant experience to Fore given his background and track record in both private and public companies. He will be a key leader in supporting the performance and growth of the company. I would like to thank Jeff Sacher from Danforth Advisors and to acknowledge his valuable contributions during his interim tenure with the company.

Mike’s hire is part of our continued investment in talent to drive and support our growth, including the recent addition of Payman Darouian, PharmD, as Senior VP, Corporate Development, Strategy and Commercial.”

“I’m excited to join Fore as chief financial officer and leverage my extensive experience from multiple high-growth biotechnology companies. This is an exciting time to join Fore, with multiple value-creating catalysts anticipated in the near-term and going forward across the trials. I believe the company and its lead asset plixorafenib are well positioned for significant growth and look forward to helping shape Fore’s future and its mission to reset the standard for BRAF treatment,” said Mr. Byrnes.

About FORE Biotherapeutics

Fore Bio is a precision oncology company dedicated to developing innovative treatments that provide better outcomes for patients with the hardest-to-treat cancers. The Company’s lead asset plixorafenib (FORE8394; formerly PLX8394) is a V600 and non-V600 BRAF inhibitor with manageable clinical safety and early efficacy signals in an ongoing Phase 1/2a clinical trial. The Fore Bio research and development team is optimizing drug development by identifying existing compounds with known clinical profiles and a clear path through clinical development to advance new medicines for patients without treatment options. For more information, please visit www.fore.bio or follow us on X (formerly Twitter) and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240812082028/en/